Bayer faces second investor reckoning over glyphosate litigation

spike

FRANKFURT (Reuters) – Bayer (BAYGn.DE) on Tuesday faces its second annual investor reckoning over its handling of a wave of U.S. lawsuits claiming its glyphosate-based weedkillers cause cancer.

FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay

Criticism from investors at this year’s annual shareholders’ meeting – held in a virtual format as gatherings are banned due to the coronavirus – will likely be less scathing than it was in 2019.

Bayer shares have plunged by

Read More

Bayer more stringent in glyphosate settlement talks due to downturn

spike

FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020. REUTERS/Wolfgang Rattay

FRANKFURT (Reuters) – German drugs and pesticides company Bayer said the economic downturn due to the coronavirus has prompted it to take a tougher stance in talks to settle claims its glyphosate-based weedkillers cause cancer.

The pandemic has significantly slowed the mediation process, it said in a statement on Monday.

“The company will consider a deal only if it is financially reasonable and puts in place a mechanism

Read More

Proxy advisers split over endorsing Bayer management at AGM

spike

FRANKFURT (Reuters) – Shareholder advisory groups are divided over whether to endorse the management and directors at German drugs and pesticides company Bayer (BAYGn.DE), according to recommendations submitted by proxy voting firms.

FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020. REUTERS/Wolfgang Rattay/File Photo

Bayer is due to host its annual general meeting on April 28 but the company still faces potentially huge litigation risks stemming from its $63 billion purchase of Monsanto in 2018.

One leading

Read More